BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33772548)

  • 1. PBK/TOPK promotes chemoresistance to oxaliplatin in hepatocellular carcinoma cells by regulating PTEN.
    Cao H; Yang M; Yang Y; Fang J; Cui Y
    Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):584-592. PubMed ID: 33772548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
    Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
    J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway.
    Yang QX; Zhong S; He L; Jia XJ; Tang H; Cheng ST; Ren JH; Yu HB; Zhou L; Zhou HZ; Ren F; Hu ZW; Gong R; Huang AL; Chen J
    Cancer Lett; 2019 Jun; 452():90-102. PubMed ID: 30914208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.
    Huang H; Chen J; Ding CM; Jin X; Jia ZM; Peng J
    J Cell Mol Med; 2018 Jun; 22(6):3238-3245. PubMed ID: 29602203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.
    Ma J; Zeng S; Zhang Y; Deng G; Qu Y; Guo C; Yin L; Han Y; Cai C; Li Y; Wang G; Bonkovsky HL; Shen H
    Cancer Lett; 2017 Dec; 411():117-129. PubMed ID: 28987388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
    Cao F; Yin LX
    Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling.
    Chen G; Qiu H; Ke SD; Hu SM; Yu SY; Zou SQ
    World J Gastroenterol; 2013 Apr; 19(16):2481-91. PubMed ID: 23674849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1-Induced p62 Transcription in HCC.
    Ma L; Xu A; Kang L; Cong R; Fan Z; Zhu X; Huo N; Liu W; Xue C; Ji Q; Li W; Chu Z; Kang X; Wang Y; Sun Z; Han Y; Liu H; Gao X; Han J; You H; Zhao C; Xu X
    Hepatology; 2021 Dec; 74(6):3213-3234. PubMed ID: 34322883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.
    Shih MC; Chen JY; Wu YC; Jan YH; Yang BM; Lu PJ; Cheng HC; Huang MS; Yang CJ; Hsiao M; Lai JM
    Oncogene; 2012 May; 31(19):2389-400. PubMed ID: 21996732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulated miR-328 suppressed cell invasion and growth in hepatocellular carcinoma via targeting PTEN.
    Liang F; Cui ZJ; Liu JD; Liu KP; Li L; Chen YL
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6324-6332. PubMed ID: 30338800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway.
    Li Y; Ye Y; Feng B; Qi Y
    J Cell Biochem; 2017 Dec; 118(12):4498-4507. PubMed ID: 28464252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of β-Catenin signaling in hepatocellular carcinoma.
    Yang YF; Pan YH; Cao Y; Fu J; Yang X; Zhang MF; Tian QH
    Oncotarget; 2017 Jul; 8(29):47195-47205. PubMed ID: 28525379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-31-5p regulates chemosensitivity by preventing the nuclear location of PARP1 in hepatocellular carcinoma.
    Que KT; Zhou Y; You Y; Zhang Z; Zhao XP; Gong JP; Liu ZJ
    J Exp Clin Cancer Res; 2018 Nov; 37(1):268. PubMed ID: 30400960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment.
    Zhang F; Hu K; Liu W; Quan B; Li M; Lu S; Chen R; Ren Z; Yin X
    Cell Mol Gastroenterol Hepatol; 2023; 15(3):573-591. PubMed ID: 36513250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma.
    He F; Yan Q; Fan L; Liu Y; Cui J; Wang J; Wang L; Wang Y; Wang Z; Guo Y; Huang G
    Hum Pathol; 2010 Mar; 41(3):415-24. PubMed ID: 19954816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
    Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T
    Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of Notch1 inhibits the invasion of human hepatocellular carcinoma HepG2 and MHCC97H cells through the regulation of PTEN and FAK.
    Hu YJ; Li HY; Qiu KJ; Li DC; Zhou JH; Hu YH; Zhang FM
    Int J Mol Med; 2014 Oct; 34(4):1081-6. PubMed ID: 25110169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma.
    Ohashi T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Imamura T; Kiuchi J; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
    Br J Cancer; 2017 Jan; 116(2):218-226. PubMed ID: 27898655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.